PCM
AIMT

Pentwater Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Pentwater Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,501,200
Closed -$86.2M – 295
2020
Q3 		$86.2M Buy
+2,501,200
New +$53.3M 1.11% 19

Pentwater Capital Management's AIMT Position: Q4 2020 in Review

Pentwater Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,501,200 shares — an estimated $86.2M sold.

Pentwater Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $86.2M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Pentwater Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Pentwater Capital Management sold 2,501,200 Aimmune Therapeutics shares in Q4 2020, an estimated $86.2M.
  • Pentwater Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Pentwater Capital Management's Aimmune Therapeutics position peaked at $86.2M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Pentwater Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.